Allarity Therapeutics, Inc. 8-K

What Happened Allarity Therapeutics, Inc. filed a Current Report on Form 8-K reporting (Item 7.01) that beginning May 11, 2026 the company will use a new corporate presentation in investor and analyst presentations, and (Item 8.01) announcing its Chief Executive Officer has been invited to speak at Precision Medicine Forum Europe 2026 in Stockholm on May 11–12, 2026. The corporate presentation is furnished as Exhibit 99.1 and the company’s press release about the speaking engagement is filed as Exhibit 99.2 (dated May 8, 2026).

Key Details

• Filing date: Form 8-K filed May 8, 2026.
• Corporate presentation to be used beginning May 11, 2026; furnished as Exhibit 99.1.
• CEO invited to speak at Precision Medicine Forum Europe 2026, scheduled May 11–12, 2026 in Stockholm; press release furnished as Exhibit 99.2 (dated May 8, 2026).
• No financial results, material agreements, or management changes were reported in this filing.

Why It Matters This 8-K updates investors that Allarity is rolling out an investor presentation and that its CEO will have public visibility at a major industry conference next week. These are disclosure and investor-relations items that can increase company visibility and provide updated messaging to analysts and shareholders, but the filing does not disclose any new financial information or material corporate actions.